{
    "clinical_study": {
        "@rank": "139419", 
        "arm_group": [
            {
                "arm_group_label": "RoActemra/Actemra Q3W", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "RoActemra/Actemra Q4W", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label Phase IV study will evaluate the efficacy, safety, pharmacokinetics,\n      pharmacodynamics and immunogenicity of RoActemra/Actemra (tocilizumab) in reduced dose\n      frequency in patients with adequately controlled systemic juvenile idiopathic arthritis who\n      have experienced a laboratory abnormality on twice weekly RoActemra/Actemra dosing. Patients\n      will receive RoActemra/Actemra 12 mg/kg or 8 mg/kg intravenously every 3 weeks. After 4\n      consecutive infusions, patients who experience an event of neutropenia, thrombocytopenia or\n      liver enzyme abnormality will move to every 4 weeks RoActemra/Actemra administration.\n      Anticipated time on study treatment is 52 weeks."
        }, 
        "brief_title": "A Study of Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Juvenile Idiopathic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Arthritis", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children 2 to 17 years of age inclusive at screening\n\n          -  Systemic juvenile idiopathic arthritis (sJIA) according to International League of\n             Associations for Rheumatology (ILAR) classification (2001)\n\n          -  JADAS-71 score of 3.8 or less and absence of fever (related to sJIA) at screening and\n             baseline\n\n          -  Neutropenia, thrombocytopenia, or elevated ALT/AST previously experienced on the\n             labeled dose (Q2W) of RoActemra/Actemra at any time\n\n          -  Must meet one of the following:\n\n        Not receiving methotrexate (MTX) or discontinued MTX at least 4 weeks prior to baseline\n        visit, or Taking MTX for at least 12 weeks immediately prior to the baseline visit and on\n        a stable dose of </= 20 mg/m2 for at least 8 weeks prior to the baseline visit, together\n        with either folic acid or folinic acid according to local standard of care\n\n          -  Not currently receiving oral corticosteroids, or taking oral corticosteroids at a\n             stable dose for a minimum of 2 weeks prior to baseline visit at no more than 10\n             mg/day or 0.2 mg/kg/day, whichever is less\n\n          -  Not taking non-steroidal anti-inflammatory drug (NSAIDs), or taking no more than 1\n             type of NSAID at a stable dose for a minimum of 2 weeks prior to the baseline visit,\n             with the dose being less than or equal to the maximum recommended daily dose\n\n        Exclusion Criteria:\n\n          -  Wheelchair bound or bedridden\n\n          -  Any other auto-immune, rheumatic disease, or overlap syndrome other than sJIA\n\n          -  Pregnant or lactating, or intending to become pregnant during study conduct and up to\n             12 weeks after the last administration of study drug\n\n          -  Any significant concurrent medical or surgical condition which would jeopardize the\n             patient's safety or ability to complete the trial\n\n          -  History of significant allergic or infusion reactions to prior RoActemra/Actemra\n             infusion, and/or presence of anti-tocilizumab antibodies at screening\n\n          -  Inborn conditions characterized by a compromised immune system\n\n          -  Known HIV infection or other acquired forms of immune compromise\n\n          -  Any active acute, subacute, chronic or recurrent bacterial, viral, or systemic fungal\n             infection\n\n          -  History of atypical tuberculosis (TB)\n\n          -  Active TB requiring treatment within 2 years prior to the screening visit\n\n          -  Positive for hepatitis B or hepatitis C infection\n\n          -  Chronic hepatitis, viral or autoimmune\n\n          -  Significant cardiac or pulmonary disease\n\n          -  History of or current cancer or lymphoma\n\n          -  Uncontrolled diabetes mellitus\n\n          -  History of or concurrent serious gastrointestinal disorders\n\n          -  History of macrophage activation syndrome (MAS) within 3 months prior to screening\n             visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734382", 
            "org_study_id": "WA28029", 
            "secondary_id": "2012-000444-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "RoActemra/Actemra Q3W", 
                "description": "12 mg/kg (for patients < 30 kg) or 8 mg/kg (for patients </= 30 kg) iv every 3 weeks, up to 52 weeks", 
                "intervention_name": "tocilizumab [RoActemra/Actemra]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "RoActemra/Actemra Q4W", 
                "description": "Following 4 consecutive 3-weekly infusions: 12 mg/kg  (for patients < 30 kg) or 8 mg/kg (for patients </= 30 kg) iv every 4 weeks, up to 40 weeks", 
                "intervention_name": "tocilizumab [RoActemra/Actemra]", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "1270"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "1425"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T3B 6A8"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L1"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt/Main", 
                        "country": "Germany", 
                        "zip": "60316"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sankt Augustin", 
                        "country": "Germany", 
                        "zip": "53757"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "Lazio", 
                        "zip": "00165"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "state": "Liguria", 
                        "zip": "16147"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "Veneto", 
                        "zip": "35128"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico", 
                        "zip": "06720"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miexico City", 
                        "country": "Mexico", 
                        "zip": "06700"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "SE-171 76"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom", 
                        "zip": "L12 2AP"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Argentina", 
                "Canada", 
                "Germany", 
                "Italy", 
                "Mexico", 
                "Spain", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: WA28029 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Efficacy: Juvenile Arthritis Disease Activity Score (JADAS-71)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Occurrence of juvenile idiopathic arthritis (JIA) flares", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "removed_countries": {
            "country": [
                "Australia", 
                "Norway"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734382"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamics: Interleukin-6/C-reactive protein serum concentrations", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Immunogenicity: Anti-tocilizumab antibodies", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Patients reported outcomes: Childhood Health Assessment Questionnaire (CHAQ)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Patient reported outcomes: Parent/patient global assessment of disease activity", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}